About Immutep
Immutep (ASX:IMM) is a clinical-stage biotechnology company that is developing novel LAG-3 (lymphocyte-activation gene 3) targeted immunotherapies for cancer and autoimmune diseases. LAG-3 is a cell surface molecule that acts as a checkpoint inhibitor, regulating the activity of T cells, a type of immune cell that plays a critical role in fighting cancer and disease. Immutep's operations are focused on the development and commercialization of its LAG-3 targeted immunotherapies. The company has a portfolio of three clinical-stage and two earlier-stage product candidates. Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3 protein that is currently in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Snapshot
Operations
Products and/or services of Immutep
- Development of LAG-3 targeted immunotherapies for cancer: Immutep is developing a range of LAG-3 targeted immunotherapies for cancer, including eftilagimod alpha (IMP321), a soluble recombinant LAG-3 protein that acts as an agonist of antigen presenting cells (APCs).
- Development of T cell receptor (TCR) therapies for cancer: Immutep is developing TCR therapies for cancer, including T cell engaging bispecific antibodies (TEBs) that redirect T cells to tumour cells expressing specific tumour antigens.
- Development of bispecific antibody therapies for cancer: Immutep is developing bispecific antibody therapies for cancer, including TEBs and other bispecific antibodies that target different tumour antigens.
- Development of combination therapies for cancer: Immutep is developing combination therapies for cancer, which combine LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies with other cancer treatments, such as chemotherapy and radiation therapy.
- Licensing of Immutep's technologies to other companies: Immutep licences its technologies to other companies, which allows these companies to develop their own LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies.
- Provision of consulting and support services to other companies developing cancer immunotherapies: Immutep provides consulting and support services to other companies developing cancer immunotherapies, such as advice on preclinical and clinical development, regulatory strategy, and manufacturing.
Immutep executive team
- Mr. Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director
- Ms. Deanne Miller LLBCOO, General Counsel & Joint Company Secretary
- Dr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Executive Director
- Mr. Christian Mueller BBA, MSc.Chief Development Officer
- Dr. Stephan Winckels M.D., Ph.D.Chief Medical Officer
- Ms. Indira NaiduJoint Company Secretary